PAC Partners released its latest research report on Anatara Lifesciences (ANR). The report provided a SPEC BUY rating and a price target of $0.90 per share.
“Life after Zoetis”
Please open the attached PDF to view the report.
PAC Partners released its latest research report on Anatara Lifesciences (ANR). The report provided a SPEC BUY rating and a price target of $0.90 per share.
“Life after Zoetis”
Please open the attached PDF to view the report.